Why the study?
Some patients develop ischemic stroke despite taking direct oral anticoagulants due to other risk factors such as coagulopathies.
Warfarin therapy followed by percutaneous LAA closure may be a feasible and effective strategy for patients with non-valvular atrial fibrillation and antithrombin-III deficiency who experience embolic events on direct oral anticoagulants.
Answers are grounded in this paper and cite their sources.
AT-III deficiency may underlie stroke on rivaroxaban in NVAF; leaves open whether targeted testing improves outcomes.
Some patients develop ischemic stroke despite taking direct oral anticoagulants because of the presence of other risk factors such as coagulopathies. A 65-year-old male patient with non-valvular atrial fibrillation (NVAF) taking rivaroxaban was diagnosed as having embolic stroke and antithrombin-III (AT-III) deficiency. Echocardiography revealed a thrombus in the left atrial appendage (LAA). He was prescribed warfarin, and after resolution of the thrombus, we successfully performed percutaneous LAA closure (LAAC), with no subsequent recurrence or device-related thrombosis. Warfarin and LAAC may be feasible for NVAF patients with AT-III deficiency.
No takes yet. Share an insight, caveat, or question.
Shimohama et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: